MLN8054
- Generic Name
- MLN8054
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H15ClF2N4O2
- CAS Number
- 869363-13-3
- Unique Ingredient Identifier
- BX854EHD63
- Background
MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00652158
- Locations
- 🇪🇸
Ciutat Sanitaria Vall d'Hebron, Barcelona, Spain
A Study of MLN8054 in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00249301
- Locations
- 🇺🇸
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath